JP2019528288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528288A5 JP2019528288A5 JP2019510324A JP2019510324A JP2019528288A5 JP 2019528288 A5 JP2019528288 A5 JP 2019528288A5 JP 2019510324 A JP2019510324 A JP 2019510324A JP 2019510324 A JP2019510324 A JP 2019510324A JP 2019528288 A5 JP2019528288 A5 JP 2019528288A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cells
- composition according
- agents
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 210000002865 immune cell Anatomy 0.000 claims 15
- 231100000433 cytotoxic Toxicity 0.000 claims 14
- 230000001472 cytotoxic effect Effects 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229960000485 methotrexate Drugs 0.000 claims 5
- DYCJFJRCWPVDHY-LSCFUAHRSA-N NBMPR Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(SCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 DYCJFJRCWPVDHY-LSCFUAHRSA-N 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 102100024263 CD160 antigen Human genes 0.000 claims 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- 108010022394 Threonine synthase Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 239000012650 DNA demethylating agent Substances 0.000 claims 2
- 229940045805 DNA demethylating agent Drugs 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims 1
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229940055760 yervoy Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023031570A JP7609908B2 (ja) | 2016-08-18 | 2023-03-02 | がん免疫療法のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376680P | 2016-08-18 | 2016-08-18 | |
| US62/376,680 | 2016-08-18 | ||
| PCT/US2017/047515 WO2018035413A1 (en) | 2016-08-18 | 2017-08-18 | Compositions and methods for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023031570A Division JP7609908B2 (ja) | 2016-08-18 | 2023-03-02 | がん免疫療法のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528288A JP2019528288A (ja) | 2019-10-10 |
| JP2019528288A5 true JP2019528288A5 (https=) | 2020-10-01 |
| JP7239463B2 JP7239463B2 (ja) | 2023-03-14 |
Family
ID=61197093
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510324A Active JP7239463B2 (ja) | 2016-08-18 | 2017-08-18 | がん免疫療法のための組成物および方法 |
| JP2023031570A Active JP7609908B2 (ja) | 2016-08-18 | 2023-03-02 | がん免疫療法のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023031570A Active JP7609908B2 (ja) | 2016-08-18 | 2023-03-02 | がん免疫療法のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20210205361A1 (https=) |
| EP (2) | EP3500262A4 (https=) |
| JP (2) | JP7239463B2 (https=) |
| KR (1) | KR102659468B1 (https=) |
| CN (1) | CN110099687A (https=) |
| AU (1) | AU2017313828B2 (https=) |
| CA (1) | CA3033876A1 (https=) |
| ES (1) | ES2983739T3 (https=) |
| SG (1) | SG11201901347UA (https=) |
| WO (1) | WO2018035413A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2496244B8 (en) | 2009-11-02 | 2017-11-22 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| CN115137752A (zh) * | 2015-08-25 | 2022-10-04 | Uab研究基金会 | 用于干细胞移植的方法 |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| CN112585166A (zh) | 2018-06-23 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法 |
| CA3118696A1 (en) * | 2018-11-08 | 2020-05-14 | The Uab Research Foundation | Compositions and methods for treating cancer |
| CN110511906A (zh) * | 2019-05-16 | 2019-11-29 | 安徽瑞达健康产业有限公司 | 一种细胞组合物在癌细胞smmc-7721上的应用 |
| WO2021245095A1 (en) * | 2020-06-02 | 2021-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to improve immunotherapies |
| EP4281082A4 (en) | 2021-01-21 | 2024-12-18 | National Taiwan University | METHOD OF TREATMENT OF CANCER |
| CN113476609A (zh) * | 2021-08-05 | 2021-10-08 | 南京医科大学 | 一种替莫唑胺与次黄嘌呤-鸟嘌呤磷酸核苷转移酶小分子抑制剂组合物及其应用 |
| WO2023021113A1 (en) * | 2021-08-18 | 2023-02-23 | Julius-Maximilians-Universität Würzburg | Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs) |
| CN117264906A (zh) * | 2023-09-18 | 2023-12-22 | 北京大学第三医院（北京大学第三临床医学院） | 一种靶向PD-L1的γδT细胞及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US7078034B2 (en) | 1999-01-28 | 2006-07-18 | Palmetto Health Alliance | In vitro activated γ δ lymphocytes |
| EP2496244B8 (en) | 2009-11-02 | 2017-11-22 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| EP2968601A1 (en) * | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
-
2017
- 2017-08-18 WO PCT/US2017/047515 patent/WO2018035413A1/en not_active Ceased
- 2017-08-18 JP JP2019510324A patent/JP7239463B2/ja active Active
- 2017-08-18 CN CN201780056996.XA patent/CN110099687A/zh active Pending
- 2017-08-18 AU AU2017313828A patent/AU2017313828B2/en active Active
- 2017-08-18 ES ES20154049T patent/ES2983739T3/es active Active
- 2017-08-18 EP EP17842178.0A patent/EP3500262A4/en not_active Withdrawn
- 2017-08-18 SG SG11201901347UA patent/SG11201901347UA/en unknown
- 2017-08-18 KR KR1020197007398A patent/KR102659468B1/ko active Active
- 2017-08-18 US US16/065,552 patent/US20210205361A1/en not_active Abandoned
- 2017-08-18 EP EP20154049.9A patent/EP3673911B1/en active Active
- 2017-08-18 CA CA3033876A patent/CA3033876A1/en active Pending
-
2019
- 2019-02-18 US US16/278,336 patent/US20190381100A1/en not_active Abandoned
- 2019-12-16 US US16/715,692 patent/US20200188436A1/en not_active Abandoned
-
2023
- 2023-03-02 JP JP2023031570A patent/JP7609908B2/ja active Active
-
2024
- 2024-11-25 US US18/958,046 patent/US20250313803A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528288A5 (https=) | ||
| Rousseau et al. | Anti-TIGIT therapies for solid tumors: a systematic review | |
| Niu et al. | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ | |
| Tong et al. | ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma | |
| Lu et al. | Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party | |
| Kaushik et al. | The evolutionary legacy of immune checkpoint inhibitors | |
| Jia et al. | PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy | |
| Qin et al. | New advances in immunotherapy for non-small cell lung cancer | |
| Zatloukal et al. | A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease | |
| Kang et al. | Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer | |
| Mediavilla-Varela et al. | A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment | |
| Mucileanu et al. | PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies | |
| Nakamura et al. | Targeting cancer‐related inflammation in the era of immunotherapy | |
| Yoo et al. | A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | |
| Chae et al. | Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma | |
| Li et al. | Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy | |
| CN106456756B (zh) | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 | |
| Abdou et al. | Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies | |
| KR102659468B1 (ko) | 암 면역요법을 위한 조성물 및 방법 | |
| KR20180004740A (ko) | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 | |
| Galluzzi et al. | Novel immune checkpoint blocker approved for the treatment of advanced melanoma | |
| JP2022524559A (ja) | がん遺伝子によって促進されるがんの処置 | |
| van Erp et al. | Targeting anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma (RMS) with the second-generation ALK inhibitor ceritinib | |
| Verma et al. | Immunotherapy in extensive small cell lung cancer | |
| Shen et al. | Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling |